72219-19-3

Basic information

• Product Name: Phenol, 4-(1-pyrrolidinylmethyl)-
• CAS NO: 72219-19-3
• Molecular Formula: C11H15NO
• Molecular Weight: 177.246
• Mol File: 72219-19-3.mol
• Article Data: 9

Chemical Properties

• CAS DataBase Reference: Phenol, 4-(1-pyrrolidinylmethyl)-(CAS DataBase Reference)
• NIST Chemistry Reference: Phenol, 4-(1-pyrrolidinylmethyl)-(72219-19-3)
• EPA Substance Registry System: Phenol, 4-(1-pyrrolidinylmethyl)-(72219-19-3)

Safety Data

• Hazardous Substances Data: 72219-19-3(Hazardous Substances Data)

Upstream product

• 142335-64-6 4-(pyrrolidin-1-ylmethyl)aniline 
• 133851-67-9 1-(4-nitro-benzyl)-pyrrolidine 
• 123-75-1 pyrrolidine 
• 123-08-0 4-hydroxy-benzaldehyde 
• 100-14-1 4-nitrobenzyl chloride 
• 123-11-5 4-methoxy-benzaldehyde 

Downstream Products

• 142335-65-7 2-(4-Pyrrolidin-1-ylmethyl-phenoxy)-propionic acid ethyl ester 
• 1234202-15-3 4-(pyrrolidin-1-ylmethyl)phenyl-3-(1H-indol-3-yl)propanoate 
• 1234202-13-1 4-(pyrrolidin-1-ylmethyl)phenyl-2-(1H-indol-3-yl)acetate 
• 1354792-29-2 tert-butyl 3-(4-(pyrrolidin-1-ylmethyl)phenoxy)azetidine-1-carboxylate 
• 1354791-20-0 (5-(4-chlorophenyl)-1,3,4-oxadiazol-2-yl)(3-(4-(pyrrolidin-1-ylmethyl)phenoxy)azetidin-1-yl)methanone 

Relevant articles and documents

Synthesis and biological evaluation of a new class of multi-target heterocycle piperazine derivatives as potential antipsychotics

In this study, we designed and synthesized a novel series of multi-receptor ligands as polypharmacological antipsychotic agents by using a multi-receptor affinity strategy. Among them,3wcombines a multi-receptor mechanism with high mixed affinities for D

Discovery of (3-(4-(2-Oxa-6-azaspiro[3.3]heptan-6-ylmethyl)phenoxy)azetidin-1-yl)(5-(4-methoxyphenyl)-1,3,4-oxadiazol-2-yl)methanone (AZD1979), a Melanin Concentrating Hormone Receptor 1 (MCHr1) Antagonist with Favorable Physicochemical Properties

A novel series of melanin concentrating hormone receptor 1 (MCHr1) antagonists were the starting point for a drug discovery program that culminated in the discovery of 103 (AZD1979). The lead optimization program was conducted with a focus on reducing lipophilicity and understanding the physicochemical properties governing CNS exposure and undesired off-target pharmacology such as hERG interactions. An integrated approach was taken where the key assay was ex vivo receptor occupancy in mice. The candidate compound 103 displayed appropriate lipophilicity for a CNS indication and showed excellent permeability with no efflux. Preclinical GLP toxicology and safety pharmacology studies were without major findings and 103 was taken into clinical trials.

Design, synthesis, and evaluation of 2-phenoxy-indan-1-one derivatives as acetylcholinesterase inhibitors

A series of 2-phenoxy-indan-1-one derivatives have been designed, synthesized, and tested as acetylcholinesterase inhibitors. The most potent compound exhibited high AChE inhibitory activity (IC50 = 50 nM), and the molecular docking study indicated that it was nicely accommodated by AChE.